ACTI Stock Overview
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Active Biotech AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.54 |
| 52 Week High | kr1.48 |
| 52 Week Low | kr0.40 |
| Beta | 0.35 |
| 1 Month Change | -4.91% |
| 3 Month Change | -32.67% |
| 1 Year Change | -32.67% |
| 3 Year Change | -64.34% |
| 5 Year Change | -83.82% |
| Change since IPO | -98.34% |
Recent News & Updates
Recent updates
Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?
Feb 19
Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely
Jul 27Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely
May 07Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation
Nov 09We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely
May 03We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate
Jan 18
Shareholder Returns
| ACTI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.9% | 0.2% | 1.8% |
| 1Y | -32.7% | -4.3% | 10.7% |
Return vs Industry: ACTI underperformed the Swedish Biotechs industry which returned -4.3% over the past year.
Return vs Market: ACTI underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| ACTI volatility | |
|---|---|
| ACTI Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ACTI's share price has been volatile over the past 3 months.
Volatility Over Time: ACTI's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 8 | Helen Tuvesson | www.activebiotech.com |
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd.
Active Biotech AB (publ) Fundamentals Summary
| ACTI fundamental statistics | |
|---|---|
| Market cap | kr196.06m |
| Earnings (TTM) | -kr45.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.3x
P/E RatioIs ACTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACTI income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr45.80m |
| Earnings | -kr45.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACTI perform over the long term?
See historical performance and comparison